Skip to main content
Clinical Trials/CTRI/2014/09/005011
CTRI/2014/09/005011
Recruiting
未知

Clinical outcomes and patient satisfaction following Laser Blended Vision for presbyopia correction using MeL 90 platform - LBV

Research Foundation Nethradhama Eye Hospital0 sites50 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- healthy individuals in presbyopic age group
Sponsor
Research Foundation Nethradhama Eye Hospital
Enrollment
50
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Research Foundation Nethradhama Eye Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\.Subjects medically suitable for LASIK,
  • 2\. Presbyopic with corrected distant visual acuity(CDVA) no worse than 20/25 in either eye
  • 3\. Tolerance of at least \-0\.75 D anisometropia
  • 4\. Myopic patients with spherical equivalent (SE) refraction \-8\.50 D in both eyes
  • 5\. Hyperopic patients with SE upto \+5\.75 D in both eyes
  • 6\. Willing to accept a slight difference in vision between both eyes 8\. Willing to use prescription corrective lenses to enhance vision to do precision tasks(reading small prints, needlework)
  • 7\. Soft contact lens discontinued for minimum 1 week and Rigid Gas Permeable contact lens discontinued for minimum 3 week
  • 8\.Ability to understand and willingness to sign informed consent and participate in follow up visits

Exclusion Criteria

  • 1\.Eyes with dense amblyopia with BSCVA \< 6/12
  • 2\.Evidence of ocular diseases like severe meibomian gland diseases, herpetic keratitis, uvietis, glaucoma.
  • 3\.Visually significant cataract, retinal diseases like retinal dystrophies or diabetic retinopathy.
  • 4\.Corneal pathologies like corneal dystrophies , keratoconus, H/o corneal trauma or surgery within flap zone
  • 5\.Dry eye status\-Schirmer’s I value less than 10 mm
  • 6\.Long term ocular medication like ß blockers.
  • 7\. Patients on systemic medication likely to affect wound healing like corticosteroids or antimetabolites.
  • 8\.H/o immunocompromised state or pregnancy or nursing mothers .
  • 9\.Patients with unrealistic expectations.

Outcomes

Primary Outcomes

Not specified

Similar Trials